Wells Messersmith

Professor and Cancer Center Director

University of Colorado Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (32)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Oligometastatic pancreatic cancer is a distinct clinical entity with limited metastatic burden. This unique subset of patients harbor a favorable tumor biology and potentially better prognosis compared to widespread metastatic disease. This review explores definitions of oligometastatic pancreatic cancer and the current state of management, including systemic therapy, surgery, and locoregional techniques. While there are few randomized clinical trials directing the management of oligometastatic pancreatic cancer, we provide insights into the treatment challenges, evolving therapeutic approaches, and future directions for this unique subset of patients.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Importance The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy on overall survival (OS) is unclear because current studies do not account for the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen. Objective To investigate the association of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX with OS, taking into account the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen. Design, Setting, and Participants This retrospective cohort study included patients with localized pancreatic adenocarcinoma treated with 2 to 11 cycles of preoperative (m)FOLFIRINOX followed by resection across 48 centers in 20 countries from 2010 to 2018. Patients who died within 3 months after surgery were excluded (landmark). Data were analyzed from February 1 to December 31, 2023. Exposures Preoperative (m)FOLFIRINOX chemotherapy followed by resection and eventually followed by adjuvant chemotherapy. Main Outcomes and Measures The primary outcome was OS, calculated from the 3-month landmark. Cox regression analysis, including interaction analyses, was performed to investigate the association of adjuvant chemotherapy with OS. Results Overall, 767 patients were included after resection of pancreatic adenocarcinoma (median [IQR] age, 62 [55-67] years; 404 [52.7%] male). Adjuvant chemotherapy was independently associated with prolonged OS (hazard ratio [HR], 0.66; 95% CI, 0.49-0.87), confirmed by adjusted OS curves. The interaction analysis to assess estimated treatment effect across subgroups was not statistically significant. The forest plot and interaction test suggest that the association of adjuvant chemotherapy was lower among patients receiving 8 or more cycles of preoperative (m)FOLFIRINOX, those who had radiological response, and those with ypN0 disease. Compared to no adjuvant chemotherapy, both adjuvant (m)FOLFIRINOX (HR, 0.57; 95% CI, 0.40-0.80) and other multiagent adjuvant regimens (HR, 0.61; 95% CI, 0.41-0.92) were associated with prolonged OS, whereas single-agent adjuvant chemotherapy was not (HR, 0.75; 95% CI, 0.55-1.03). Conclusions and Relevance In this cohort study, adjuvant (m)FOLFIRINOX and other multiagent chemotherapy regimens were associated with improved OS following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX, whereas single-agent adjuvant chemotherapy was not. The impact of adjuvant chemotherapy on OS may be lower in subgroups such as patients with 8 or more preoperative cycles of (m)FOLFIRINOX, those having radiological response, and those with ypN0.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (44)

Shivaani Kummar

Oregon Health & Science University

UNITED STATES
View details

Matthew Reilley

Assistant Professor

University of Virginia School of Medicine

UNITED STATES
View details

Mariano Ponz-Sarvise

Universidad de Navarra

SPAIN
View details

Oliver Strobel

Head of Department, Professor of Visceral Surgery

Medical University of Vienna

AUSTRIA
View details

Junxiao Hu

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Alessandro Zerbi

Director

Humanitas University

ITALY
View details

Yuan-Haw Andrew Wu

Johns Hopkins University

UNITED STATES
View details

Ammar Javed

Assistant Professor

NYU Langone Health

UNITED STATES
View details

Christopher Lieu

Associate Professor

University of Denver

UNITED STATES
View details

Niharika Mettu

Duke University

UNITED STATES
View details

Laura Pike

Sr. Professional Research Assistant

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Apostolia M. Tsimberidou

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Hiroyuki Ishida

Assistant Professor

Kansai Medical University

JAPAN
View details

Judith D. Goldberg

Professor of Population Health and Environmental Medicine

NYU School of Medicine

UNITED STATES
View details

Maria João Amaral

University of Coimbra

PORTUGAL
View details

Jennifer Diamond

Professor of Medicine with Tenure

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Gennaro Nappo

Humanitas University

ITALY
View details

Anne Noonan

Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Michael Gordon

Chief Medical Officer

-

UNITED STATES
View details

Adrie van Bokhoven

Associate Professor

University of Colorado

UNITED STATES
View details

Ian Chau

Royal Marsden Hospital Sutton

UNITED KINGDOM
View details

Isao Matsumoto

Professor

University of Tsukuba

JAPAN
View details

Todd Pitts

-

UNITED STATES
View details

Robert Lentz

Assistant Professor

University of Colorado Cancer Center

UNITED STATES
View details

Knut Jørgen Labori

Professor

Oslo University Hospital

NORWAY
View details

Hannah Robinson

Assistant Professor

The Ohio State University Wexner Medical Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sunnie S. Kim

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Michael J. Overman

-

UNITED STATES
View details

Nigel Jamieson

University of Glasgow

UNITED KINGDOM
View details

Daniel LaBarbera

Professor and Director, The CU Anschutz Center for Drug Discovery

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Teresa Macarulla

Head of Gastrointestinal and Endocrine Tumor Unit

Hospital Clínic de Barcelona

SPAIN
View details

Andrew Coveler

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Howard S Hochster

Rutgers University

UNITED STATES
View details

Nataliya Uboha

Associate Professor

University of Wisconsin-Madison Carbone Cancer Center

UNITED STATES
View details

Kirk C. Hansen

Prof

University of Colorado Boulder

UNITED STATES
View details

Jozef Urdzik

Uppsala University

SWEDEN
View details

Nick Pavlakis

Professor

University of Sydney

AUSTRALIA
View details

Alexis Leal

Assistant Professor of Medicine

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Christos Fountzilas

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Elizabeth Pando

Universitat Autònoma de Barcelona (UAB)

SPAIN
View details

Hector Esquer

Senior Research Scientist

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Julie Lang

Associate Research Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Daisuke Hashimoto

Kansai Medical University

JAPAN
View details